News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • ASML raised its 2026 revenue guide to €43–45B and is increasing capacity 30%, signaling stronger AI-driven capex demand.
  • Assembly Biosciences secured a Gilead collaboration and positive Phase 1b readouts, positioning for Phase 2 catalysts and deal upside.
  • IBM plunged after weak Z mainframe results and now trades near its 52-week low while still yielding over 3% and generating free cash flow.
  • MSCI’s high-margin index and analytics franchises support a long-biased trade despite a rich valuation and low churn.
  • Robinhood’s pullback near $100 is viewed as a buying opportunity ahead of the Robinhood Chain launch and diversified revenue growth.
  • Circle’s USDC benefits from network effects and payments integrations, suggesting new stablecoins will expand overall dollar-token demand.
  • XFLT faces a proxy contest as the board backs King Street to replace Octagon after poor NAV performance and multiple CLO defaults.

Latest Articles

Zevra Therapeutics Announces Orange Book Listing of U.S. Patent Strengthening Exclusivity for MIPLYFFA

Zevra Therapeutics Announces Orange Book Listing of U.S. Patent Strengthening Exclusivity for MIPLYFFA

Zevra Therapeutics has successfully submitted a U.S. patent for its drug MIPLYFFA to the FDA's Orange Book, strengthening its intellectual property protection with exclusivity extending to 2041. This development solidifies Zevra's position in treating Niemann-Pick disease type C and enhances the long-term commercial value of MIPLYFFA. A patent term…

Medicus Pharma Advances Teverelix® Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients with Key European Submission

Medicus Pharma Advances Teverelix® Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients with Key European Submission

Medicus Pharma announced the submission of a substantial modification application to advance its Teverelix® Phase 2b trial in Europe, targeting advanced prostate cancer patients with heightened cardiovascular risk. The trial aims to optimize dosing and support registrational development, addressing a significant unmet need in prostate cancer treatm…

Caliber to Present at Planet MicroCap Las Vegas 2026

Caliber to Present at Planet MicroCap Las Vegas 2026

Caliber, a Nasdaq-listed real estate alternative asset manager, announced it will present at the Planet MicroCap Las Vegas 2026 conference. The presentation will highlight the company's progress toward consistent profitability, capital structure improvements, real estate investment strategies in key U.S. markets, and its pioneering use of tokenizat…

Bending Spoons Files F-1 to Pursue Nasdaq Listing Under 'BSP' Ticker

Bending Spoons Files F-1 to Pursue Nasdaq Listing Under 'BSP' Ticker

Bending Spoons S.p.A. has submitted a registration statement on Form F-1 with the U.S. Securities and Exchange Commission for a potential initial public offering of its ordinary shares, seeking a listing on the Nasdaq Global Select Market under the symbol BSP. The company named a group of international banks as lead and joint book-running managers.…

Quantum Space to List via SPAC Merger in $1.2 Billion Deal

Quantum Space to List via SPAC Merger in $1.2 Billion Deal

Quantum Space has agreed to merge with SPAC Inflection Point Acquisition in a transaction that values the combined business at roughly $1.2 billion. The agreement includes a $300 million PIPE led by Inflection Point Asset Management and is intended to fund acceleration of the company's Ranger spacecraft program and expansion of manufacturing capaci…

Remy Cointreau Shares Rise After UBS Upgrades Stock on RC Forward Plan

Remy Cointreau Shares Rise After UBS Upgrades Stock on RC Forward Plan

Remy Cointreau shares climbed nearly 4% after UBS upgraded the stock to neutral from sell and raised its 12-month price target to €44. The move follows the announcement of the RC Forward transformation plan and full-year results showing mixed performance: top-line pressure, an EBIT beat, improved cash conversion, and a halved dividend.

Campbell’s Sticks to Annual Forecast as Consumer Caution Dampens Sales

Campbell’s Sticks to Annual Forecast as Consumer Caution Dampens Sales

Campbell’s Co reiterated its full-year guidance after reporting a 4% drop in third-quarter net sales, as subdued U.S. consumer spending and movement toward lower-cost and private-label brands weighed on demand. The company’s adjusted quarterly EPS beat estimates thanks to supply-chain optimization and cost-savings initiatives, but management expect…

Bank of America Sees Blurring Lines Between Betting, Crypto and Finance

Bank of America Sees Blurring Lines Between Betting, Crypto and Finance

Bank of America analysts say the distinctions between sports wagering, speculative crypto trading, and traditional financial markets are fading. The bank identifies perpetual futures and increased gamification on prediction platforms and sportsbooks as near-term areas of innovation that could open new revenue streams for betting operators.

Axolotls Flood Mexico City Imagery as World Cup Arrivals Begin

Axolotls Flood Mexico City Imagery as World Cup Arrivals Begin

As Mexico City prepares to host five World Cup matches, the axolotl - a salamander native to the region - has surfaced across murals, subway cars and public sculptures in vibrant purple. The animal's sudden prominence has produced mixed reactions: vendors and some visitors view the imagery as an opportunity to raise awareness, while local scientist…

Lilly stock rises as retatrutide data bolsters obesity franchise lead

Lilly stock rises as retatrutide data bolsters obesity franchise lead

Eli Lilly shares rose ahead of the market after the company released complete results from two retatrutide trials at the American Diabetes Association meeting. The lower 4 mg dose produced roughly 19% weight loss with tolerability comparable to existing therapies, prompting analysts to say the drug could strengthen Lilly’s leadership in the obesity…

Cerebras Shares Climb as Nine Banks Begin Buy-Focused Coverage

Cerebras Shares Climb as Nine Banks Begin Buy-Focused Coverage

Cerebras Systems (NASDAQ: CBRS) rose 4% after nine major brokerages initiated coverage following the end of the company's post-IPO quiet period. Analysts emphasized Cerebras' wafer-scale Wafer-Scale Engine (WSE), its advantage in fast inference, and sizable commercial contracts with OpenAI and AWS as the basis for aggressive revenue and market-size…

Cognizant Shares Rise After Wedbush Upgrade Citing AI Builder Momentum

Cognizant Shares Rise After Wedbush Upgrade Citing AI Builder Momentum

Cognizant Technology Solutions jumped in pre-market trading after Wedbush upgraded the stock to Outperform and boosted its price target from $56 to $70. The broker highlighted accelerating traction for Cognizant's AI Builder initiative, a 70% increase in total contract value and the prospect that large enterprise deals will convert to revenue in th…

Why Broadcom's Pullback Is a Buying Opportunity, Not a Breakdown

Why Broadcom's Pullback Is a Buying Opportunity, Not a Breakdown

Broadcom (AVGO) has pulled back sharply, but beneath the headline volatility the company retains durable secular advantages, strong free cash flow, and enterprise exposure that should support a recovery. This is a tactical long trade that aims to capture mean reversion into value and upcoming catalysts while keeping position risk-defined.